Lasa Supergenerics Limited (LASA.BO)
INR 17.88
(2.88%)
INR 17.88
(2.88%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 121.02 Million INR | -37.28% |
| 2022 | 192.97 Million INR | -54.9% |
| 2021 | 427.83 Million INR | -51.76% |
| 2020 | 886.86 Million INR | 23.62% |
| 2019 | 717.43 Million INR | 76.48% |
| 2018 | 406.51 Million INR | -42.47% |
| 2017 | 706.57 Million INR | 8.41% |
| 2016 | 651.75 Million INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 43.56 Million INR | 2450.7% |
| 2023 Q1 | 102.5 Million INR | 76.4% |
| 2023 FY | 121.02 Million INR | -37.28% |
| 2023 Q2 | 77.93 Million INR | -23.98% |
| 2023 Q3 | 24.98 Million INR | -67.94% |
| 2023 Q4 | 1.7 Million INR | -93.16% |
| 2022 Q3 | 61.67 Million INR | -20.49% |
| 2022 Q1 | -4.38 Million INR | -102.66% |
| 2022 FY | 192.97 Million INR | -54.9% |
| 2022 Q4 | 58.11 Million INR | -5.78% |
| 2022 Q2 | 77.57 Million INR | 1868.58% |
| 2021 Q1 | 143.66 Million INR | -19.07% |
| 2021 FY | 427.83 Million INR | -51.76% |
| 2021 Q4 | 164.66 Million INR | 362.27% |
| 2021 Q3 | 35.62 Million INR | -66.76% |
| 2021 Q2 | 107.15 Million INR | -25.41% |
| 2020 Q2 | 240.84 Million INR | 10.34% |
| 2020 FY | 886.86 Million INR | 23.62% |
| 2020 Q4 | 177.5 Million INR | -29.07% |
| 2020 Q1 | 218.28 Million INR | -14.05% |
| 2020 Q3 | 250.23 Million INR | 3.9% |
| 2019 FY | 717.43 Million INR | 76.48% |
| 2019 Q3 | 175.18 Million INR | 6.67% |
| 2019 Q2 | 164.23 Million INR | 32.38% |
| 2019 Q1 | 124.06 Million INR | 11.19% |
| 2019 Q4 | 253.94 Million INR | 44.96% |
| 2018 Q4 | 111.57 Million INR | 59.52% |
| 2018 Q3 | 69.94 Million INR | -34.91% |
| 2018 Q2 | 107.45 Million INR | -8.58% |
| 2018 Q1 | 117.54 Million INR | 45.3% |
| 2018 FY | 406.51 Million INR | -42.47% |
| 2017 FY | 706.57 Million INR | 8.41% |
| 2017 Q2 | 218.2 Million INR | 0.16% |
| 2017 Q4 | 80.89 Million INR | -60.2% |
| 2017 Q3 | 203.23 Million INR | -6.86% |
| 2017 Q1 | 217.86 Million INR | 0.0% |
| 2016 Q1 | 158.95 Million INR | 0.0% |
| 2016 FY | 651.75 Million INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 99.548% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.922% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 99.027% |
| Granules India Limited | 16.79 Billion INR | 99.28% |
| Indoco Remedies Limited | 6.04 Billion INR | 97.997% |
| Achyut Healthcare Limited | 4.86 Million INR | -2389.817% |
| Ajanta Pharma Limited | 21.06 Billion INR | 99.425% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.769% |
| Alpa Laboratories Limited | 188.89 Million INR | 35.927% |
| Brooks Laboratories Limited | 65.62 Million INR | -84.441% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 98.055% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 91.777% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 96.725% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.926% |
| Eris Lifesciences Limited | 10.42 Billion INR | 98.839% |
| FDC Limited | 8.33 Billion INR | 98.548% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.825% |
| Gufic Biosciences Limited | 4.16 Billion INR | 97.096% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 98.046% |
| Ipca Laboratories Limited | 29.8 Billion INR | 99.594% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 81.454% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 37.201% |
| Laurus Labs Limited | 24.62 Billion INR | 99.508% |
| Lupin Limited | 123.71 Billion INR | 99.902% |
| Mankind Pharma Limited | 44.52 Billion INR | 99.728% |
| Medicamen Biotech Limited | 495.49 Million INR | 75.574% |
| Medico Remedies Limited | 262.14 Million INR | 53.831% |
| Megasoft Limited | 342.07 Million INR | 64.618% |
| NATCO Pharma Limited | 25.73 Billion INR | 99.53% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.505% |
| RPG Life Sciences Limited | 2.48 Billion INR | 95.126% |
| Sigachi Industries Limited | 2 Billion INR | 93.955% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.953% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 97.065% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 87.157% |
| Unichem Laboratories Limited | 4.86 Billion INR | 97.512% |
| Wanbury Limited | 1.73 Billion INR | 93.007% |
| Windlas Biotech Limited | 1.33 Billion INR | 90.96% |
| ZIM Laboratories Limited | 1.26 Billion INR | 90.447% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.903% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 120.091% |
| Divi's Laboratories Limited | 32.44 Billion INR | 99.627% |
| Hester Biosciences Limited | 1.27 Billion INR | 90.497% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 97.907% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 92.224% |
| Bal Pharma Limited | 770.19 Million INR | 84.286% |
| Strides Pharma Science Limited | 14.38 Billion INR | 99.159% |
| Venus Remedies Limited | 2.18 Billion INR | 94.455% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 97.924% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 95.928% |
| Shilpa Medicare Limited | 3.54 Billion INR | 96.588% |
| Aarti Drugs Limited | 8.31 Billion INR | 98.545% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 97.358% |
| Suven Life Sciences Limited | -200.79 Million INR | 160.275% |
| Ind-Swift Limited | 2.17 Billion INR | 94.429% |
| Valiant Laboratories Limited | -60.66 Million INR | 299.509% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 99.467% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 85.946% |
| Themis Medicare Limited | 1.5 Billion INR | 91.952% |
| Hikal Limited | 3.14 Billion INR | 96.149% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.741% |
| Sequent Scientific Limited | 2.97 Billion INR | 95.937% |
| Novartis India Limited | 1.32 Billion INR | 90.879% |
| Wockhardt Limited | 16.24 Billion INR | 99.255% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 99.384% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -730.127% |
| Neuland Laboratories Limited | 8.24 Billion INR | 98.533% |
| Morepen Laboratories Limited | 6.16 Billion INR | 98.036% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 80.494% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 82.799% |